ARF-BP1 as mediator of p53 dependent and independent tumor suppression
- 技術優勢
- A novel target for cancer therapy ARF has tumor suppressor activity that is p53 independent Since ARF-BP1 interacts with ARF and p53 but not with Mdm2, it is a useful therapeutic target in tumors that lack Mdm2 activity
- 技術應用
- Assay for compounds that inhibit ARF-BP1 binding to p53 Inhibitors of ARF-BP1 binding to p53 can be further developed into potential broad spectrum cancer drugs Determination of ARF-BP1 status of tumors may have prognostic value where the cellular level of ARF-BP1 may inversely correlate with good prognosis ARF-BP1 could be used as a biomarker for pre-malignant tumors or for tumor staging and grading
- 詳細技術說明
- The present invention identifies ARF-BP1, a novel ubiquitin ligase, as a critical mediator of p53- dependent and p53-independent tumor suppression functions of ARF. ARF-BP1 directly binds and ubiquitinates p53. Inactivation of ARF-BP1 stabilizes p53 ...
- *Abstract
-
None
- *Inquiry
- Cynthia LangColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- 1694
- *Principal Investigation
-
- *Publications
- ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor. D. Chen et. al, Cell, (2005) Volume 121, Issue 7, Pages 1071-1083.
- *Web Links
- USPTO: US 7,358,335
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
